UCSF and UCLA to host inaugural PSMA PET Conference

University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.” The conference will take place online and in-person in San Francisco on January 18-19, 2024. The event is co-sponsored by UC San Francisco and UCLA, with support from the Prostate Cancer Foundation.

Register

The conference is designed to inform the physicians about the latest developments in prostate-specific membrane antigen PET imaging (PSMA PET) and radioligand therapy, including imaging interpretation and patient management. As early adopters of PSMA PET imaging and radioligand therapy, UCSF and UCLA clinicians and researchers will share their experiences and insights about future treatment directions.

Additionally, there will be cutting-edge presentations, panel discussions and exhibits from both domestic and international experts in the field, with topics including:

• How to interpret PSMA PET scans
• The selection of patients for PSMA radioligand therapy
• Patient management and potential toxicities for PSMA radioligand therapy
• Case-based tumor board discussions

The conference organizers are Thomas Hope, MD, vice chair of the UCSF Department of Radiology, and Jeremie Calais, MD, and Johannes Czernin, MD, both of the UCLA Department of Molecular and Medical Pharmacology.

Guest speakers include Michael Morris, MD, Memorial Sloan Kettering Cancer Center; Oliver Sartor, MD, Tulane Cancer Center; Louise Emmett, MD, St. Vincent’s Hospital Sydney; Matthias Eiber, MD, Technische Universität München, and Wolfgang Fendler, MD, University of Duisburg-Essen.

Registration for in-person and virtual attendance is now open.

Clinicians are also encouraged to present posters about their research work, with awards for poster presenters. The submission deadline for posters is December 1.

“We hope that this conference will be the go-to source for learning about PSMA PET and radioligand therapies, both of which are changing the landscape of prostate cancer treatment,” said Hope.

Read more at UCSF.edu

Register